Razzaghi 2017.
| Study characteristics | ||
| Methods |
Study design: randomised, double‐blind, placebo‐controlled trial Setting/location: Department of Infectious Disease, School of Medicine, Kashan University of Medical Sciences, Kashan, Iran Study duration: 12 weeks |
|
| Participants |
Sample size: n = 60 participants Inclusion criteria:
Exclusion criteria:
Participant characteristics:
|
|
| Interventions |
Intervention:
Control:
|
|
| Outcomes |
Primary outcome
|
|
| Notes | Funded by a grant from the Vice Chancellor for Research, KUMS, and Iran | |
| Risk of bias | ||
| Bias | Authors' judgement | Support for judgement |
| Random sequence generation (selection bias) | Low risk | Quote "Randomization assignment was performed using computer generated random numbers" |
| Allocation concealment (selection bias) | Low risk | Quote "Randomization and allocation were concealed from the researchers and participants until the final analyses were completed" |
| Blinding of participants and personnel (performance bias) All outcomes | Low risk | Vitamin D supplements and placebo capsules were similar in shape and size |
| Blinding of outcome assessment (detection bias) All outcomes | Low risk | Quote "Randomization and allocation were concealed from the researchers and participants until the final analyses were completed" |
| Incomplete outcome data (attrition bias) All outcomes | Low risk | All those randomised were analysed at end of study |
| Selective reporting (reporting bias) | Low risk | Study registered and all outcomes reported |
| Other bias | Low risk | None detected |